Annual Biomarkers Congress

Osaka, Japan   September 20-21, 2018

Daniel W. Chan

Daniel W. Chan

Center for Biomarker Discovery and Translation at the Johns Hopkins University


Dr. Daniel W. Chan is Professor of Pathology, Oncology, Radiology and Urology, the Director of Center for Biomarker Discovery and Translation at the Johns Hopkins University. He is also the Director of Clinical Chemistry Division and the Co-Director of Pathology Core Laboratory at the Johns Hopkins Hospital, Baltimore, Maryland, USA. Dr. Chan is a diplomat of the American Board of Clinical Chemistry (ABCC) and a fellow of the National Academy of Clinical Biochemistry (NACB). He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics. He has written 5 books, 40 book chapters and 300 scientific articles. He is funded by the National Cancer Institute (NCI) as the Principal investigator of the CPTAC (Cancer Proteomic Tumor Analysis Consortium) and the Biomarker Reference Lab for the EDRN (Early Detection Research Network). The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, and ovarian cancer biomarkers. In 1977, he conducted the clinical study of CA27.29 as a marker for breast cancer recurrence leading to the 1st FDA approval of a serum breast cancer assay. In 2000, he founded the Center for Biomarker Discovery and Translation. The focus of this Center is the discovery of proteomics biomarkers using mass spectrometry and protein microarrays, followed by the validation and translation of these novel biomarkers for the detection, diagnosis, classification, management and understanding of human diseases. In 2009, he developed the OVA1 test for ovarian cancer – the 1st FDA cleared proteomic in vitro diagnostic multivariate index assay (IVDMIA). In 2012, he developed public-private partnerships (NCI EDRN, industry and academic centers) leading to the clinical study, publication and FDA approval of new prostate cancer tests – proPSA (phi) with Beckman Coulter Inc. and PCA3 (PROGENSA) with Gen-probe (Hologic, Inc). Dr. Chan has trained over 20 clinical chemistry fellows at Johns Hopkins. Many of these scientists have become leaders and professor in Clinical Chemistry. During the last 20 years, he has given over two hundred invited lectures, both within and outside of US. Dr. Chan received numerous awards for his outstanding contributions to clinical chemistry. Examples are the inaugural Morton K. Schwartz Award for Cancer Research Diagnostics, Albert Nichols Award for strategic innovation in laboratory medicine, Norman Kubasik Award for Outstanding contribution to the education of clinical laboratory scientists, Bernard Gerulat Award for outstanding achievement in clinical chemistry, Carl R. Joliff Award for Outstanding achievement in diagnostic immunology and education, Miriam Reiner Award for outstanding contributions to research in the field of clinical chemistry and Outstanding Contribution to Clinical Chemistry in Research Award (all from the AACC). Outstanding Leadership Award (NCI-EDRN), inaugural Translational Proteomics Award (HUPO). He served as the Chair of the Proteomics Division (a founder) of the American Association for Clinical Chemistry (AACC), Board of Directors of NACB and as the President of the National Registry in Clinical Chemistry (NRCC), President of the International Society of Enzymology (ISE) and on the Board of Directors (a founder) of the US Human Proteome Organization (HUPO). He is the Editor-in-Chief of the journal Clinical Proteomics.

Research Interest

Immunoassay; Biochemical Tumor Markers - Particularly Breast and Prostate Tumor Makers; Clinical Chemistry; Proteomics,Biomarkers

Related Conferenes